Literature DB >> 35962090

Do we get better outcomes from early treatment of Class III discrepancies?

Andrew T DiBiase1, Jadbinder Seehra2, Spyridon N Papageorgiou3, Martyn T Cobourne4.   

Abstract

Early orthodontic treatment in the mixed dentition aims to simplify definitive treatment in the permanent dentition. In Class III cases, this can be an effective strategy for the management of a local anterior crossbite, using either a removable or simple fixed appliance. For more significant Class III malocclusions, the decision to intervene early is a more difficult one. Traditionally, orthodontists in the UK have been reluctant to embark on early treatment in the presence of a skeletal Class III relationship but there is now some evidence that in selected cases, the use of protraction headgear can be a successful method of avoiding the need for later surgery. Although growth prediction in Class III cases is notoriously difficult, in the presence of maxillary retrognathia, the general dental practitioner should consider early referral of Class III cases to a specialist orthodontist.
© 2022. The Author(s).

Entities:  

Mesh:

Year:  2022        PMID: 35962090      PMCID: PMC9374590          DOI: 10.1038/s41415-022-4507-0

Source DB:  PubMed          Journal:  Br Dent J        ISSN: 0007-0610            Impact factor:   2.727


  15 in total

1.  [The orthopedic treatment of skeletal class III malocclusion with maxillary protraction therapy].

Authors:  B Xu; J Lin
Journal:  Zhonghua Kou Qiang Yi Xue Za Zhi       Date:  2001-11

2.  Effect of varying the force direction on maxillary orthopedic protraction.

Authors:  Ahmet Keles; Ebru Cetinkaya Tokmak; Nejat Erverdi; Ravindra Nanda
Journal:  Angle Orthod       Date:  2002-10       Impact factor: 2.079

3.  Dentofacial effects of a modified tandem traction bow appliance.

Authors:  Zeynep Atalay; Tuba Tortop
Journal:  Eur J Orthod       Date:  2010-03-26       Impact factor: 3.075

4.  What is the value of orthodontic treatment?

Authors:  P E Benson; H Javidi; A T DiBiase
Journal:  Br Dent J       Date:  2015-02-16       Impact factor: 1.626

5.  Profile changes in patients with class III malocclusions after Delaire mask therapy.

Authors:  H Kiliçoglu; Y Kirliç
Journal:  Am J Orthod Dentofacial Orthop       Date:  1998-04       Impact factor: 2.650

6.  Fixed versus removable orthodontic appliances to correct anterior crossbite in the mixed dentition--a randomized controlled trial.

Authors:  Anna-Paulina Wiedel; Lars Bondemark
Journal:  Eur J Orthod       Date:  2014-08-11       Impact factor: 3.075

7.  Is early Class III protraction facemask treatment effective? A multicentre, randomized, controlled trial: 15-month follow-up.

Authors:  Nicky Mandall; Andrew DiBiase; Simon Littlewood; Spencer Nute; Nadia Stivaros; Ross McDowall; Inderjit Shargill; Helen Worthington; Richard Cousley; Fiona Dyer; Rye Mattick; Barbara Doherty
Journal:  J Orthod       Date:  2010-09

Review 8.  Early orthodontic treatment for Class III malocclusion: A systematic review and meta-analysis.

Authors:  See Choong Woon; Badri Thiruvenkatachari
Journal:  Am J Orthod Dentofacial Orthop       Date:  2017-01       Impact factor: 2.650

9.  Do we get better outcomes from early treatment of Class III discrepancies?

Authors:  Andrew T DiBiase; Jadbinder Seehra; Spyridon N Papageorgiou; Martyn T Cobourne
Journal:  Br Dent J       Date:  2022-08-12       Impact factor: 2.727

10.  Is early Class III protraction facemask treatment effective? A multicentre, randomized, controlled trial: 3-year follow-up.

Authors:  Nicky Anne Mandall; Richard Cousley; Andrew DiBiase; Fiona Dyer; Simon Littlewood; Rye Mattick; Spencer Nute; Barbara Doherty; Nadia Stivaros; Ross McDowall; Inderjit Shargill; Amreen Ahmad; Tanya Walsh; Helen Worthington
Journal:  J Orthod       Date:  2012-09
View more
  1 in total

1.  Do we get better outcomes from early treatment of Class III discrepancies?

Authors:  Andrew T DiBiase; Jadbinder Seehra; Spyridon N Papageorgiou; Martyn T Cobourne
Journal:  Br Dent J       Date:  2022-08-12       Impact factor: 2.727

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.